This core will be responsible for managing the SPORE and disseminating information within the SPORE and for external interactions. The Core is designed for low-cost, yet efficient administration and communication in order to focus funds on research activities. The administrative component of the Core follows an organizational diagram for management activities. Monitoring of research will occur via 1) Research Project Teams, 2) Committee of Research Project Leaders, 3) Core Investigators Committee, 4) Developmental Projects Program, 5) Career Development Committee, and 6) the central SPORE Steering Committee. An institutional Advisory Board and External Advisory Board will provide yearly formal evaluations and reports to the Steering Committee. The communication component of the Core is directed at intra-SPORE, inter-SPORE, and National Cancer Institute research activities. The Core provides travel funds for Johns Hopkins GI SPORE participation in the NCI SPORE annual meetings, to include the SPORE Director/PI, members of the Committee of Research Project Leaders and other SPORE investigators. In addition, communication of validated results to the medical community in order to impact on the incidence and mortality of colorectal and pancreatic cancer will occur via publication of SPORE findings in medical journals, occasional inter-institutional think tanks and organized public conferences through the Office of Continuing Medical Education of the Johns Hopkins Medical Institutions, news releases to medical writers and press conferences for announcement of vital advances through the Office of Public Affairs of The Johns Hopkins Medical Institutions, and when appropriate, alerts coordinated through the NCI program staff.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA062924-21
Application #
8727980
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
21
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Al Efishat, Mohammad A; Attiyeh, Marc A; Eaton, Anne A et al. (2018) Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 268:340-347
Cruz-Correa, Marcia; Hylind, Linda M; Marrero, Jessica Hernandez et al. (2018) Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology 155:668-673
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118

Showing the most recent 10 out of 883 publications